MARKET

MNMD

MNMD

Mind Medicine
NASDAQ
8.42
-0.04
-0.47%
Opening 11:57 04/25 EDT
OPEN
8.30
PREV CLOSE
8.46
HIGH
8.59
LOW
8.17
VOLUME
480.46K
TURNOVER
0
52 WEEK HIGH
12.22
52 WEEK LOW
2.410
MARKET CAP
593.62M
P/E (TTM)
-3.4440
1D
5D
1M
3M
1Y
5Y
This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even Higher
NASDAQ · 13h ago
Weekly Report: what happened at MNMD last week (0415-0419)?
Weekly Report · 3d ago
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Benzinga's psychedelic headlines roundup includes a look at the first two weeks of April 2024. Psilocybin could alter mechanisms associated with major depression and neurodegenerative diseases. Ancient Romans used to trip on hallucinogenic plants, archeologists say. Psycon's 2024 edition will take place in Colorado in May.
Benzinga · 04/17 13:13
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist on Hearings. The Drug Enforcement Administration is revisiting its stance on the classification of two psychedelic compounds. The agency has proposed both be listed as Schedule I substances with no recognized medical use. Benzinga Psychedelics Podcast features an expert on the ancient healing plant kanna.
Benzinga · 04/17 12:42
Leerink Partners Initiates Coverage of Mind Medicine (MNMD) with Outperform Recommendation
NASDAQ · 04/15 23:01
Leerink Partners Initiates Coverage On Mind Medicine with Outperform Rating, Announces Price Target of $20
Benzinga · 04/15 14:30
Weekly Report: what happened at MNMD last week (0408-0412)?
Weekly Report · 04/15 10:47
MIND MEDICINE (MINDMED) INC <MNMD.O>: LEERINK PARTNERS INITIATES COVERAGE WITH OUTPERFORM RATING AND $20 PRICE TARGET
Reuters · 04/15 10:17
More
About MNMD
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

Webull offers Mind Medicine (MindMed) Inc stock information, including NASDAQ: MNMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MNMD stock methods without spending real money on the virtual paper trading platform.